Issues

This is an original study providing, from preclinical models to patients, a reliable proof of ¹⁸FDG-PET/CT efficiency as a surrogate marker for the early evaluation of EGFR-TKI (erlotinib) efficacy that may improve diagnostic accuracy of molecular effect (ERK1/2). The image represents a facial sagittal section of an ¹⁸FDG-PET/CT of a patient with an oropharyngeal head and neck squamous cell carcinoma. It reveals a tumor ¹⁸FDG uptake before patient exposure to erlotinib. For further details, please see the article by Vergez and colleagues on page 4434 of this issue.